Standard Article

Application of Recombinant DNA Technology in Medicinal Chemistry and Drug Discovery

  1. Soumitra Basu1,
  2. Adegboyega K. Oyelere2

Published Online: 15 JAN 2003

DOI: 10.1002/0471266949.bmc023

Burger's Medicinal Chemistry and Drug Discovery

Burger's Medicinal Chemistry and Drug Discovery

How to Cite

Basu, S. and Oyelere, A. K. 2003. Application of Recombinant DNA Technology in Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery. 2:81–113.

Author Information

  1. 1

    University of Pittsburgh, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, Pittsburgh, Pennsylvania, USA

  2. 2

    Rib-X Pharmaceuticals, Inc., New Haven, Connecticut, USA

Publication History

  1. Published Online: 15 JAN 2003

This is not the most recent version of the article. View current version (15 SEP 2010)

Abstract

Drug discovery is usually a long and arduous process. However, pharmaceutical industries are making a significant progress in simplifying certain aspects of drug discovery process, especially in the area of target discovery, validation, and lead-compounds discovery. Advances in recombinant DNA technology are intimately connected with the explosion of newly identified pharmaceutically important targets, and an understanding of how these targets function to regulate biological processes of interest. This is providing new and exciting opportunities for therapeutic intervention in diseases including those diseases that were thought to be untreatable a few years back. In this chapter we describe how each stage of drug discovery, from target identification to lead generation and even clinical trials, have benefited from the tools of recombinant DNA technology.

Keywords:

  • medicinal chemistry;
  • drug discovery;
  • recombinant DNA technology;
  • protein engineering;
  • site-directed mutagenesis